CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

The Super Specialty Hospital (SSH) administration here has claimed to have achieved a medical milestone by performing CAR ...

Discover Qartemi, India's innovative CAR-T cell therapy for B-cell Non-Hodgkin Lymphoma, offering personalized and affordable ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032. PORTLAND, OR, UNITED STATES, January 28 ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...